About
Products
Knolens
KnolScapes
Knolens
Knolens SLR
Knolens
KnolQuest
Knolens
Edge
Knolens
DataNexus
Platform
Solutions
KnolSights
Signup For Free
MapLight Therapeutics Initiates Phase 2 Trial for ML-007C-MA in Schizophrenia
MapLight Therapeutics has begun a Phase 2 clinical trial (ZEPHYR) to assess the efficacy, safety, and tolerability of ML-007C-MA, a novel M1/M4 muscar...
Copyright © 2025. All rights reserved
About
Terms of Service
Privacy Policy
Home/
KnloSights/
Clinical Trial Updates/
MapLight Therapeutics Initiates Phase 2 Trial for ML-007C-MA in Schizophrenia